Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

May 23, 2017

Ventilation Holes in Cigarette Filters Have Increased Lung Cancer, Study Reports

News

The light cigarettes that the tobacco industry markets as healthier have actually increased lung cancer, according to a study. That’s because the ventilation holes the industry began adding to the ... Read more

April 6, 2017

Alecensa Improves Progression-Free Survival in Certain Lung Cancer Patients

News

It took a significantly longer time for non-small lung cancer patients who received Roche’s Alecensa (alectinib) to have their disease progress than those who received chemotherapy, according to a Phase 3 clinical ... Read more

February 21, 2017

Only High-Risk Current, Ex-Smokers Should Get Lung Cancer Screening, Study Says

News

Restricting lung cancer screening to only high-risk former smokers makes economic sense, a new study shows. The study, “Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based ... Read more

February 7, 2017

Lung Cancer Patients With Anxiety, Depression Don’t Live as Long, Study Says

News

Advanced lung cancer patients who experience anxiety and depression after their diagnosis don’t live as long as those without the psychological burdens, a study shows. The research, “Anxiety after diagnosis ... Read more

January 31, 2017

Infinity Presents Positive Early Data on Therapy for NSCLC, Other Solid Tumors

News

Infinity Pharmaceuticals recently presented pre-clinical and clinical data from the company’s oral therapy candidate IPI-549 in solid tumors. The data was presented during the plenary session “PI3K Pathways in Immunology, ... Read more

January 19, 2017

Older NSCLC Patients See Many Doctors, Multiple Medications, in Months After Treatment

News

Older patients with early stage non-small-cell lung cancer (NSCLC) see an average of 20 physicians over multiple visits, and take 12 medications after a typical treatment, researchers found in a study ... Read more

January 10, 2017

Genprex Reports Positive Interim Data from Oncoprex, Tarceva Combo Trial in Advanced NSCLC

News

Genprex announced that its immunogene therapy candidate Oncoprex in combination with Genentech’s Tarceva (erlotinib) demonstrated positive Phase 2 interim trial results in patients with late-stage non-small cell lung cancer (NSCLC). The ... Read more

December 20, 2016December 20, 2016

Tagrisso Found Superior to Alimta-Chemo Combo in Specific NSCLC Patients, Trial Shows

News

Results from the Phase 3 AURA study show that Tagrisso (osimertinib) is clinically superior to the combination of Alimta (pemetrexed) plus platinum-based chemotherapy in the treatment of certain patients with non-small-cell ... Read more

December 8, 2016

Positive Phase 2 Study Results Reported for Brigatinib in NSCLC Patients

News

Ariad Pharmaceuticals reported clinical results from its pivotal ALTA Phase 2 trial that evaluated the safety and effectiveness of brigatinib in ALK-positive non-small cell lung cancer (NSCLC) patients whose disease progressed while ... Read more

November 17, 2016November 20, 2016

Participants Sought for Clinical Trial Combining Opdivo and IPI-549 to Treat Advanced Solid Tumors

News

Bristol-Myers Squibb Company and Infinity Pharmaceuticals have entered a clinical trial collaboration to evaluate the PD-1 inhibitor Opdivo (nivolumab) in combination with the PI3K-gamma inhibitor IPI-549 in patients with advanced solid tumors. The clinical trial ... Read more